NASDAQHealth CareHealthcare PlansSnapshot 2026-07-23
Reading CLOV? Create a free portfolio, then add this holding for ongoing Reports and tracking. Track it in a free portfolio. No credit card.
Create your account →A long-form read on the 1–3 year hold thesis. Slower and deeper than the daily snapshot — it refreshes only when the evidence moves.
CLOV represents a turnaround investment with a focus on improving profitability and membership growth. The current thesis state is stable, as recent financial performance is strong, but the company faces risks from litigation and management transitions.
The market currently prices CLOV as relatively cheap compared to its peers, with a notable expectations gap. This suggests that investors may not fully anticipate the potential for future profitability and revenue growth.
Management is on track to achieve GAAP profitability and grow Medicare Advantage membership significantly. However, there is a near-term risk of missing earnings estimates, which could impact sentiment.
The thesis hinges on the performance of sector bellwethers like UNH, CVS, and ELV, as their earnings results will influence CLOV's momentum. Additionally, management's ability to navigate recent litigation and maintain operational stability is crucial.
Over the next 1 to 3 years, CLOV's trajectory will depend on its execution of growth plans and external market conditions. Not investment advice.
The most important moves since the prior daily snapshot.
Our read on the company is unchanged since the prior snapshot.
as of 2026-07-23
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Why it matters: Achieving GAAP profitability is a key goal for Clover. It shows financial health.
Confirms:Management confirms GAAP net income guidance of $0M to $20M for 2026.
Disproves:Management lowers GAAP net income guidance to below $0M for 2026.
Why it matters: The court ruling on the Star Rating impacts future payments and overall financial health.
Confirms:Court ruling confirms a higher Star Rating for Clover Insurance.
Disproves:Court ruling maintains or lowers the 2026 Star Rating.
Why it matters: Earnings will show if Clover is on track for GAAP profitability in 2026. Investors will focus on net income and revenue growth.
Confirms:Clover reports Q2 2026 net income of $10M or more. This shows progress towards making money.
Disproves:Clover reports a net loss over $5M. This shows challenges in making money.
Why it matters: If Clover makes a profit in Q2, it shows they can be profitable in 2026.
Confirms:Q2 2026 GAAP Net Income reported above $0 million.
Disproves:Q2 2026 GAAP Net Income reported below $0 million.
Why it matters: Changes in leaders can change company goals and affect investor trust.
Confirms:A new CEO is named, giving clear leadership direction.
Disproves:No new CEO is named, causing ongoing uncertainty.
Why it matters: Revenue growth is important for Clover's finances and future plans.
Confirms:Management says total revenue grew by 49% from last year for 2026.
Disproves:Total revenue growth is less than 30% compared to last year.
Why it matters: Membership growth is key to revenue targets and overall business health.
Confirms:Medicare Advantage will have 154,000 to 158,000 members by the end of 2026.
Disproves:Membership growth falls below 46% year-over-year by Q3 2026.
Why it matters: Revenue growth is crucial for achieving the 49% increase target for 2026.
Confirms:Q2 total revenues increase year over year by more than 15%.
Disproves:Total revenues grow less than 5% year over year.
Why it matters: The outcome may impact Clover's 2026 Star Rating and future payments.
Confirms:Court ruling favors Clover, restoring the 2026 Star Rating.
Disproves:Court ruling against Clover, maintaining the 3.5 Star Rating.
Why it matters: Recent changes in the CEO and CFO could affect plans and actions. Stability is key for investor trust.
Confirms:Clover appoints a new CEO and CFO, providing a clear leadership direction.
Disproves:If more leaders leave or if leadership is unclear, it may worry investors.
Why it matters: Revenue growth is important for the company to make more money.
Confirms:Total revenue reported between $2.81B and $2.92B for 2026.
Disproves:Total revenue growth falls below 49% year-over-year by Q3 2026.
Why it matters: Sustaining or exceeding a 46% growth rate in membership is key for future revenues.
Confirms:Medicare Advantage membership grew by 46% or more compared to last year.
Disproves:Medicare Advantage membership grew by less than 46% compared to last year.
Why it matters: Total revenues need to grow to meet the full-year guidance of 49% growth.
Confirms:Total revenues in Q2 2026 were more than $749 million.
Disproves:Total revenues in Q2 2026 were less than $749 million.
Why it matters: More people using Clover Assistant can lower medical costs. It can also boost profits.
Confirms:Clover Assistant use was over 40% among members.
Disproves:Clover Assistant use was below 40% among members.
